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Abstract
Background: 17q11.2 microdeletions, which include the neurofibromatosis type 1 (NF1) gene region, are responsible
for the NF1 microdeletion syndrome, observed in 4.2% of all NF1 patients. Large deletions of the NF1 gene and its
flanking regions are associated with a more severe NF1 phenotype than the NF1 general population.
Case presentation: We hereby describe the clinical and molecular features of two girls (aged 2 and 4 years, respectively),
with non-mosaic atypical deletions. Patient 1 showed fifteen café-au-lait spots and axillary freckling, as well as
a Lisch nodule in the left eye, strabismus, high-arched palate, malocclusion, severe kyphoscoliosis, bilateral calcaneovalgus
foot, mild generalized hypotonia, hyperactivity and deficits of speech-related abilities. NF1 genomic rearrangements
through multiplex ligation-dependent probe amplification (MLPA) detected an heterozygous deletion of the whole
NF1 gene. Array comparative genomic hybridization (a-CGH) analysis defined a 17q11.2 deletion of about 1 Mb
(breakpoints at positions 29,124,299 and 30,151,654), which involved different genes (partially CRLF3, ATAD5, TEFM,
ADAP2, RNF135, OMG, EVI2B, EVI2A, RAB11FIP4), including NF1. Patient 2 showed growth and developmental delay,
supravalvular pulmonary stenosis, twenty-five café-au-lait spots, axillary freckling, craniofacial dysmorphic features,
short neck with pterygium, limb abnormalities and foci of neural dysplasia on brain magnetic resonance imaging
(MRI). MLPA detected an heterozygous deletion of NF1, which was detailed by a-CGH indicating the positions 29,
124,299 and 30,326,958 as its breakpoints, and which included aside from the genes deleted in Patient 1 also COPRS,
UTP6 and partially SUZ12. Fluorescent in situ hybridization (FISH) analysis of the parents documented a de novo origin
of the deletions in both cases.
Conclusions: The present report will likely provide further insights and a better characterization of NF1 microdeletion
syndrome.
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Background
Neurofibromatosis type 1 (NF1; MIM#162200) is a neu-
rogenetic disorder with a birth prevalence estimated
around 1:2500 [1]. NF1 shows an autosomal dominant
pattern of inheritance and wide phenotypical variability.
Café-au-lait spots (CALs), cutaneous and/or subcutane-
ous neurofibromas (CNFs/SCNFs), skinfold freckling,
skeletal abnormalities and Lisch nodules of the iris are
its main clinical features. NF1 patients have an increased
risk of learning and intellectual disabilities as well as
tumors of the nervous system and other organs [1]. NF1
gene maps on chromosome 17q11.2. Microdeletions of
this region are responsible for NF1 microdeletion
syndrome, observed in 4.2% of all NF1 patients. Large
deletions of NF1 and its flanking regions have been asso-
ciated with more severe phenotype than NF1 general
population. Four types (1, 2, 3 and atypical) of such large
NF1 deletions have been reported so far, with differences
in size, breakpoint location, number of genes deleted
and somatic mosaicism [2]. Type-1 is the most frequent
(70–80%), while 8–10% are atypical [3]. In the present
study we report on the clinical and molecular features of
two patients with non-mosaic atypical NF1 deletions, in
order to give further insights and a better characterization
of NF1 microdeletion syndrome.
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This 4-year-old female was the first born, at 35 weeks of
gestation, by vaginal delivery. Family and pregnancy
histories were uneventful. At birth her weight was 2400
g (62nd percentile), length 45 cm (46th percentile), and
occipitofrontal circumference (OFC) 31.3 cm (41st per-
centile). At the time of the presentation, her weight was
14.700 kg (25th percentile), height 104 cm (50th to 75th
percentile) and OFC 49.5 cm (25th to 50th percentile).
She had fifteen café-au-lait spots (mainly located in the
nuchal and gluteal regions, the left elbow and the poster-
ior surface of the right lower limb) and axillary freckling
(Fig. 1), as well as a Lisch nodule in the left eye, strabis-
mus, high-arched palate and malocclusion. Severe kyphos-
coliosis and bilateral calcaneovalgus foot were also noted.
The neuropsychiatric evaluation, by Wechsler Preschool
and Primary Scale of Intelligence (WPPSI) [4] and Pea-
body Picture Vocabulary Test-III (PPVT-III), showed
deficits of speech-related abilities (Table 1).
Mild generalized hypotonia, dysgraphia (she went to
primary school and was evaluated after the full school
reading, writing and calculation skills attained by the
first four months) and hyperactivity completed her
clinical profile at the age of 6. Brain MRI and US heart
evaluation showed no abnormalities.
No pathogenic mutations were revealed by molecular
analysis of the NF1 and SPRED1 genes, through amplifi-
cation of the coding regions and the flanking intronic
sequences and sequencing of the amplified regions.
Then, NF1 genomic rearrangements through multiplex
ligation-dependent probe amplification (MLPA) were
performed, and the heterozygous deletion of the whole
NF1 gene was detected. Array comparative genomic
hybridization (a-CGH) analysis (100–150 Kb resolution,
genomic assembly GRCh37.p13) defined a 17q11.2 dele-
tion of about 1Mb, and identified the breakpoints at
positions 29,124,299 and 30,151,654. The deleted region
involved different genes (partially CRLF3, ATAD5, TEFM,
ADAP2, RNF135, OMG, EVI2B, EVI2A, RAB11FIP4), in-
cluding NF1. The rearrangement was confirmed by fluor-
escent in situ hybridization (FISH) (Additional file 1).
Patient 2
This 2-year-8-month-old female was the second born by
vaginal delivery, from healthy non-consanguineous parents,
at 37+ 5 weeks of gestation after an uneventful pregnancy.
At birth her weight was 2860 g (34th percentile), length 45
cm (4th percentile), OFC 31 cm (3rd percentile). At 8
months of age her weight, length and OFC were 6670 g
(3rd to 10th percentile), 66 (3rd to 10th percentile) and 42
cm (3rd to 10th percentile), respectively. At her first neuro-
developmental examination at 18months old, a global
developmental delay was observed. EEG was normal, while
US heart evaluation showed mild supravalvular pulmonary
stenosis (pressure gradient <50mmHg).
At the age of 2, because of her growth delay, cardio-
myopathy and dysmorphic features, sequencing of the
genes PTPN11, RAF1, BRAF1, MEK1/2, KRAS, SOS1
and SHOC2 were performed. No abnormalities were
detected. Plasma amino acid pattern, plasma and urine
levels of glycosaminoglycans, acylcarnitine profile and
urine organic acids were normal.
At the time of the presentation, her weight was 10.160
kg (<10th percentile), height 83 cm (<10th percentile)
and OFC 47.3 cm (<10th percentile). She had twenty-five
café-au-lait spots (mainly located in the anterior
thoracic-abdominal region, upper back, posterior surface
of the left thigh and proximal extremity of the right
Fig. 1 Patient 1: axillary frackling
Table 1 Neuropsychiatric evaluation. Patient 1 profile has been
evaluated by WPPSI-IV (Wechsler Preschool and Primary Scale of
Intelligence for children younger than 6 yr of age)
WPPSI-IV (Wechsler Intelligence Scale for children)
Total IQ 88 (within normal value)
Verbal IQ 71 (low value)
Performance IQ 122 (within normal value)
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lower limb) and axillary freckling, as well as craniofacial
dysmorphic features (broad forehead, dysplasic and low-
set ears with thick helix, synophris, receding orbital roof
with exophthalmos, hypertelorism, depressed nasal bridge,
bulbous nose, malar hypoplasia, long and prominent phil-
trum, thick lips) and short neck with pterygium. Pectus
excavatum, wide-spaced nipples, supernumerary areola,
diastasis recti abdominis with prominent abdomen were
also noted (Fig. 2). Short hands and feet, clinodactyly of
the 5th finger, deep palmar creases and bilateral genu val-
gum and pes plano-valgus were observed (Fig. 2). Brain
MRI revealed corpus callosum hypoplasia, T2 hyperinten-
sities near the fourth ventricle, periventricular hyperinten-
sities and a hyperintense nodule in the left thalamus,
which were thought as foci of neural dysplasia with defect
of myelination.
During a follow-up visit her cognitive profile was evalu-
ated by WPPSI-IV for children younger than 6 yr of age,
leading to the diagnosis of a mild intellectual disability
(Table 2).
Molecular analysis of the genes NF1 and SPRED1,
through amplification of the coding regions and the
flanking intronic sequences and sequencing of the amp-
lified regions did not detect any pathogenic mutations.
Therefore, NF1 genomic rearrangements through MLPA
were performed, and identified an heterozygous deletion
of NF1. a-CGH (100–150 Kb resolution, genomic assem-
bly GRCh37.p13) detailed a deletion of 1.2 Mb, and indi-
cated the positions 29,124,299 and 30,326,958 as the
breakpoints of the deletion, which included aside from the
genes deleted in Patient 1 also COPRS, UTP6 and partially
SUZ12. FISH was performed in both subjects aside from
peripheral blood leucocytes also on buccal swab DNA,
confirming the rearrangement also in peripheral tissue
and ruling out somatic mosaicism (Additional file 1).
Familial gene analysis
In both children and their parents, all exonic and intronic
regions of NF1 gene and its flanking regions were ampli-
fied through polymerase chain reaction (PCR), and the
products were purified and directly sequenced. FISH
analysis revealed in both cases a de novo origin of
rearrangements.
Discussion and conclusions
17q11.2 microdeletions, encompassing NF1 gene, are
responsible for NF1 microdeletion syndrome [5], which
include dysmorphic features, neurodevelopmental delay,
cardiovascular defects, overgrowth, a higher tumor bur-
den and earlier onset of benign neurofibromas and
malignant peripheral nerve sheath tumors (MPNST)/
other malignancies [2]. It represents 4.2% of all NF1
patients. The first 17q11.2 microdeletion patient was
reported in 1992. Since then, more than 150 subjects
have been described [6].
Fig. 2 Patient 2: note café-au-lait spots, pectus excavatum, wide-
spaced nipples, diastasis recti abdominis with prominent abdomen
and bilateral genu valgum and pes plano-valgus
Table 2 Neuropsychiatric evaluation. Patient 2 profile has been
evaluated by WPPSI-IV (Wechsler Preschool and Primary Scale of
Intelligence for children younger than 6 yr of age)
WPPSI-IV (Wechsler Intelligence Scale for children)
Total IQ 55 (low value)
Verbal IQ 64 (low value)
Performance IQ 61 (low value)
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Four types of large NF1 deletion have been identified (1,
2, 3 and atypical), recognizable by size, breakpoint loca-
tion, number of genes deleted and somatic mosaicism [2].
Type-1 NF1 deletion patients, whose anomaly encom-
passes 1.4Mb and comprises 14 protein-coding genes
and 4 microRNA genes, are the most frequent (70–80%).
Type-2 extends for 1.2Mb and depends on hemizygosity
of 13 genes, sparing LRRC37B (about 10%). Type-3 is very
rare (1–4%), spanning 1.0Mb for a total of 9 genes [3].
Atypical deletions do not show recurrent breakpoints and
are heterogeneous in size and genes deleted (8–10%) [2].
Unlike the well documented clinical phenotype of type-1
NF1 deletions, a more detailed characterization of patients
with atypical NF1 deletions is lacking.
Here we have presented two de novo non-mosaic
atypical deletions detected by MLPA, and defined through
a-CGH, in two girls with developmental delay and
dysmorphic features of variable clinical expressivity and
severity.
No pathogenic mutations were firstly revealed by mo-
lecular analysis of the NF1 and SPRED1 genes, through
amplification of the coding regions and the flanking in-
tronic sequences and sequencing of the amplified regions.
However, these tests do not allow the identification of
genomic rearrangements like gain or losses of genetic ma-
terial. Therefore, NF1 genomic rearrangements through
multiplex ligation-dependent probe amplification (MLPA)
were performed, and the heterozygous deletion of the
whole NF1 gene was detected.
The deletions of our probands cannot be classified as
type 1, 2 or 3, because the breakpoints do not harbor
within the low-copy repeats which are recurrent for such
deletions (NF1-REPa, b and c), but outside of them
(Fig. 3). Particularly, present deletions do not or partially
encompass genes typically involved in such rearrange-
ments (i.e. CRLF3, SUZ12, LRRC37B in the case of type-
1 and 2), as well as affect genes that are usually spared
(i.e. CRLF3, ATAD5, TEFM, ADAP2 and RNF135 in
type-3) (Fig. 3, modified from Kehrer-Sawatzki et al. [2]).
a-CGH profiles show the three types of recurrent (typ-
ical) deletions (type-1, 2 and 3) included within the low--
copy repeats (NF1-REPa and c), compared with our
Patient 1 and 2 atypical deletions. Cen centromeric
direction, tel telomeric direction.
Both children were clinically evaluated according to
the criteria of National Institutes of Health (NIH) for
NF1 [7], revised by Gutmann et al. [8]. They fulfilled
two criteria (≥6 CALs and axillary/inguinal freckling for
both) of the seven established for NF1 diagnosis (includ-
ing also ≥2 CNFs/SCNFs or 1 plexiform neurofibroma,
typical bone lesions, ≥2 Lisch nodules of the iris, optic
nerve glioma, an affected first degree relative).
The association between wide NF1 deletions and a
phenotype which is more severe than the NF1 general
population, presenting a higher prevalence of learning
disabilities, dysmorphic features and increased tumor
risk, has been reported [9] and it is consistent with our
experience. Specifically, type 1 microdeletion phenotype
Fig. 3 Schema of the genome region at 17q11.2 harboring the NF1 gene and its flanking genes
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includes facial dysmorphic features, overgrowth/tall-for-
age stature, cognitive delay, scoliosis, bone cysts, large
hands and feet, hyperflexibility of joints and muscular
hypotonia [2]. The clinical manifestations are related to
both the number and type of deleted genes, which in
turn has an influence on the genotype-phenotype inter-
action. Indeed, 17q11.2 microdeletion has been considered
as a contiguous gene syndrome, in which the involvement
of some of the genes contiguous to NF1 may modify the
phenotype of patients [3]. This may explain the wide
clinical variability among microdeletion patients including
the two patients here described, which are located at the
extremes of the phenotypic spectrum. Comparing the
clinical features of our two patients with type-1 NF1
deletions, a partial phenotypic overlap may be observed.
In particular, facial dysmorphisms, neurodevelopmental
delay, hypotonia, cardiovascular defects (only in Patient 2),
hands/feet anomalies, and kyphoscoliosis (only in Patient
1). Conversely, overgrowth/tall-for-age stature and high
tumor load (significantly more frequent in non-mosaic
type-1 and 2) are currently absent in our probands,
although they cannot be excluded over time. As described
above, Patient 1 phenotype is milder than Patient 2
(Table 3).
Haploinsufficiency of genes within the critical interval
could modify the phenotype of present children. To esti-
mate the likely effect of the deleted genes, the probabil-
ity of loss-of-function (LoF) intolerance should be
considered, differentiating genes in LoF intolerant or tol-
erant [2]. Specifically, 5 genes (CRLF3, ATAD5, RAB11-
FIP4, SUZ12 and LRRC37B) were predicted to be LoF
intolerant [2], which means that they could have clinical
consequences if present in one copy [5]; 4 of them (2
partially) are deleted in our subjects.
RNF135 (ring finger protein 135, MIM:611358), encodes
an E3 ubiquitin ligase. This protein contains a ring finger
domain, which may be involved in protein-protein and
protein-DNA interactions. The gene, expressed in many
different tissues (including the cortex and cerebellum), is
deleted in both probands. It could be responsible for the
dysmorphic facial features of our patients, in agreement
with literature data [2]. Its haploinsufficiency may also
contribute to the reduced cognitive abilities observed in
NF1 microdeletion patients [2], and then be related to the
specific developmental profile of our children. Further-
more, its mutations have been recently documented to be
linked to overgrowth and glioblastoma cells in vivo and
in vitro, as well as autism, suggesting for patients carrying
its deletion, an even more individualized and careful
neuropsychiatric and oncologic follow-up.
Similarly, also abnormalities of OMG (oligodendrocyte
myelin glycoprotein, MIM:164345), deleted in both of
our subjects, seem to be involved in autism spectrum
disorders, schizophrenia and intellectual disability [10].
Its transcribed protein plays a key role in the early stages
of brain development, likely regulating neurogenesis. In-
deed, it belongs to myelin-associated inhibitor proteins
(MAIPs) which are central nervous system regeneration
inhibitors. Since MAIPs are involved in regulating
synapses, abnormal expression of these proteins may
cause intellectual disability and other brain disorders [2].
Mutations of ADAP2 (ArfGAP with dual PH domains
2, MIM:608635) may contribute to the cardiovascular
malformations noted in patients with NF1 microdeletions
[11, 12]. The gene is highly expressed during early stages
of cardiac embryogenesis. The protein encoded by this
gene binds beta-tubulin and increases the stability of mi-
crotubules. Specifically, cytoskeletal defects of myocytes,
due to such altered proteins, may lead to the cardiovascu-
lar malformations observed in NF1 microdeletion patients.
Although deleted in both probands, cardiac involvement
given by supravalvular pulmonary stenosis is present only
in Patient 2. This could be explained since SUZ12 and
UTP6, expressed during the development of human heart
and deleted only in Patient 2, may contribute either co-
operatively or additively to the cardiomyopathy.
As suggested by definition, atypical large NF1 deletions
do not have recurrent breakpoints and are heterogeneous
in size and genes deleted [2]. However, the extent of the
deletion may be important in the context of genotype-
phenotype relationships in such patients. Indeed, our
study suggests that these subjects may exhibit most of the
clinical features reported in germline type-1 NF1 dele-
tions. A severe form of the disease is not limited, then, to
type-1 deletions, but it may also occur in non-mosaic
atypical ones, depending on the extent of the rearrange-
ment and the genes deleted.
Patient 1 shows a neurodevelopmental profile charac-
terized by language disorder without cognitive impair-
ment, and mild craniofacial dysmorphisms (high-arched
palate). We propose a correlation between the smaller
number of genes/regulatory elements of such deletion
and milder clinical manifestations. Therefore, although
the clinical characteristics of NF1 microdeletion patients
are usually more severe, this particular form of neuro-
fibromatosis should not be excluded “a priori” even in
the presence of patients who show a mild clinical picture
(Patient 1), especially in pediatric age, when many of the
typical features of the syndrome (i.e. CNFs or SCNFs,
MPNST, etc. …) are not yet manifest. Conversely, the
more severe clinical picture of Patient 2 may be due to
involvement of the genes COPRS, UTP6 and SUZ12 (the
latter predicted to be LoF intolerant). COPRS (coordin-
ator of PRMT5 and differentiation stimulator) is widely
expressed in human tissues, mostly in testis and brain
[13], and has been associated with overgrowth as well as
learning disabilities and dysmorphic features of NF1
microdeletion patients. It encodes an adaptor protein
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binding to protein-arginine methyltransferase 5 (PRMT5)
and to hystone H4. Such COPRS-PRMT5 complex regu-
lates cell differentiation, and is then involved in tumorigen-
esis. UTP6 (UTP6 small subunit processome component)
and SUZ12 (SUZ12 polycomb repressive complex 2 sub-
unit, MIM:606245) may be associated with congenital
heart defects [11], and together with COPRS they may
contribute to the increased tumour risk associated with
NF1 microdeletion [14]. However, although their haploin-
sufficiency could exert additive negative effects on the
phenotype of Patient 2, no conclusions can be drawn yet
with regards to their role in the specific phenotype. The
limited number of microdeletion patients together with the
imprecise definition of their boundaries, especially in atyp-
ical deletions, make it quite difficult to establish reliable
genotype-phenotype correlations [15]. Then, genetic ana-
lysis, not always performed in the past, is actually a diag-
nostic step in characterizing a patient with or suspected of
NF1. In case of microdeletion, a-CGH is an important tool
to finely define deletions. Although NF1 diagnosis is still
based on clinical criteria, information obtained from
genetic analysis can be an important instrument to plan a
more individualized clinical follow-up.
Phenotypical variability is observed in NF1 microdele-
tion patients, even in cases of identical germline deletions
[16]. Hence, the phenotype associated with NF1 microde-
letions is likely to be influenced by genetic elements such
as the expression variations of non-deleted genes and/or
the presence of feature-specific modifier genes. In
addition, epigenetic factors such as the expression of the
wild-type alleles of the genes present in one copy could
play a role. Environmental factors may also interact with
both of them. An extended comparative analysis of a
larger number of age-matched patients with additional
overlapping features may allow a more precise clinical and
genomic characterization [17]. This is also useful to
achieve a better genotype-phenotype correlation.
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